Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib (clinicaltrials.gov) - Oct 28, 2026 - P1 | N=30 | Recruiting | Sponsor: University of Chicago | Not yet recruiting ➔ Recruiting
Adverse events • Enrollment open • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|